Shrikant Chauhan of Kotak Securities feels that one should sell Sun Pharma.
Chauhan told CNBC-Awaaz, "One can sell Sun Pharma with one month view. The stoploss should keep at Rs 600. We can see level of Rs 560 at down side."
The company's trailing 12-month (TTM) EPS was at Rs 13.36 per share. (Dec, 2011). The stock's price-to-earnings (P/E) ratio was 44.90. The latest book value of the company is Rs 64.51 per share. At current value, the price-to-book value of the company was 9.3. The dividend yield of the company was 0.58%.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.